UFPTUFP Technologies, Inc.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though at the top of its own P/E range.
Expensive vs its own history: P/E 32.0 vs a 23.5 median over 41 quarters (+36% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What UFPT's price assumes
UFP Technologies, Inc. trades at 32.0× earnings against 28.1× for the median Medical Devices name, more expensive than its own group.
Trailing P/E · Medical Devices median 28.1 · 1.14× the median: the market pays up for this one
- Price / sales
- 3.64
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 4.97
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 3.81
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 4.97
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 25.0
- EV / salestoday's price, trailing year to Jun 30, 2026
- 3.81
- Healthcare median P/E503 names
- 27.9
- Medical Devices median P/E64 names
- 28.1
- Market capitalisation7.7 million shares, counted Jul 27, 2026
- $2.30B
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $197.53 |
| Its own P/E history, median | $217.63 |
| Its own P/E history, upper quartile | $264.79 |
| 52-week range | $185.28 – $333.88 |
| Today | $296.83 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.